Treatment of Polycythemia Vera

ABSTRACT

The selection of treatment for patients with polycythemia vera (PV) still is the subject of much discussion among hematologists. It is emphasized that important physiologic and pathogenic components of the illness relate not only to the erythroid cell, but also to the megakaryocyte. Both play essential roles in causing complications of the disease. Hematologists agree that the mainstay in treatment remains phlebotomy, a basic pillar of the concept of primum non nocere. In general, the target levels for the hematocrit have been accepted as ≤ 45% for men and ≤ 42% for women. Low-dose aspirin, 80 to 100 mg daily, should be used as a basic component of therapy. The selection of the type of treatment for those patients who require some form of myelosuppression owing to the frequency of phlebotomy and/or its complications provides the basis for major discussion, confrontation, and disagreement. For the most part, alkylating agents are avoided owing to the established risk of secondary leukemia, but these drugs and radioactive phosphorous (³²P) still play a role in treating the very elderly patient or for those who have significant comorbid conditions. Whereas hydroxyurea remains the most frequently prescribed drug, limitations to its use as a therapeutic agent of choice include questions regarding its effectiveness, toxicity, and potential leukemogenicity. Interferon offers a rational choice of treatment owing to its broad physiologic effects on hematopoiesis. Whereas its effect in treating patients with PV is unequivocal, it is associated with side effects even when used properly. Moreover, it has only modest effect on Janus kinase 2 (JAK2) expression. Clearly, the best treatment for patients with PV is still sought. Perhaps more explicit exploitation of the JAK2 abnormality found in PV (and other myeloproliferative diseases) may provide more effective agents in the future.

Polycythemia vera - phlebotomy - aspirin - hydroxyurea - JAK2 - interferon - radioactive phosphorus

REFERENCES

• 1 Messinezy M, Pearson T C, Pochazka A et al.. Treatment of primary proliferative polycythemia by venisection and low-dose busulphan. Retrospective study from one centre.  Br J Haematol. 1985;  61 657-666
• 2 Pearson T C, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythaemia.  Lancet. 1978;  2 1219-1222
• 3 Berlin N I. Diagnosis and classification of the polycythemias.  Semin Hematol. 1975;  12 339-351
• 4 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  10 2224-2232
• 5 Tefferri A, Spivak J L. Polycythemia vera: scientific advances and current practice.  Semin Hematol. 2005;  42(4) 206-220
• 6 Silver R T. Long-term results in the treatment of polycythemia vera with interferon.  Cancer. 2006;  , In press
• 7 Michiels J J, Abels J, Steketee J et al.. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.  Ann Intern Med. 1985;  102 466-471
• 8 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low-dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350(2) 114-124
• 9 Berk P D, Wasserman L R, Fruchtman S M et al.. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin N Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia; WB Saunders 1995: 166-194
• 10 Kaplan M E, Mack K, Goldberg J B et al.. Long term management of polycythemia vera with hydroxyurea: a progress report.  Semin Hematol. 1986;  23 167-171
• 11 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  10 2224-2232
• 12 Nand S, Messmore H, Fisher S G et al.. Leukemia transformation in polycythemia vera: analysis of risk factors.  Am J Hematol. 1990;  34 32-36
• 13 Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with thererapeutic implications.  Eur J Haematol. 1994;  52 134-139
• 14 Najean Y, Rain J D. Treatment of polycythemia vera-the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.  Blood. 1997;  90 3370-3377
• 15 Kaung D T, Swartzendruber A A. Effect of chemotherapeutic agents on chromosomes of patients with lung cancer.  Dis Chest. 1969;  55 98-100
• 16 Landaw S A. Acute leukemia in polycythemia vera. In: Wasserman LR, Berk PD, Berlin N Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia; WB Saunders 1995: 154-165
• 17 Silver R T. Recombinant interferon-alpha for treatment of polycythemia vera.  Lancet. 1988;  2 403
• 18 Silver R T. A new treatment for polycythemia vera: recombinant interferon alfa.  Blood. 1990;  76 664-665
• 19 Silver R T. Interferon-a2b: a new treatment for polycythemia vera.  Ann Intern Med. 1993;  119 1091-1092
• 20 Silver R. Interferon alpha: effects of long-term treatment for polycythemia vera.  Semin Hematol. 1997;  34 40-50
• 21 Lengfelder E, Berger U, Hehlmann R. Interferon in the treatment of polycythemia vera.  Ann Hematol. 2000;  79 103-109
• 22 Sacchi S, Leoni P, Liberati M et al.. A respective comparison between treatment with phlebotomy alone and with interferon alpha in patients with polycythemia vera.  Ann Hematol. 1994;  68 247-250
• 23 Taylor P C, Dolan G, Ng J P et al.. Efficacy of recombinant interferon-alpha (rIFN-a) in polycythemia vera: a study of 17 patients and an analysis of published data.  Br J Haematol. 1996;  92 55-59
• 24 Hino M, Futami E, Okuno S et al.. Possible selective effects of interferona-2b on a malignant clone in a case of polycythemia vera.  Ann Hematol. 1993;  66 161-162
• 25 Messora C, Be Qsi L, Vecchi A et al.. Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha.  Br J Haematol. 1994;  86 402-404
• 26 Means R T, Krantz S B. Inhibition of human erythroid colony-forming units can be corrected by recominant human erythropoietin.  Blood. 1991;  78 2564-2567
• 27 Chott A, Gisslinger H, Thiele J et al.. Interferon-alpha induced morphological changes of megakaryocytes: a histomorphological study on bone marrow biopsies in chronic myeloproliferative disorders with excess thrombocytoses.  Br J Haematol. 1990;  74 10-16
• 28 Wang O, Miyakawa Y, Fox N et al.. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1.  Blood. 2000;  96 2093-2099
• 29 Sinzinger H, Linkesch W, Ludwig H et al.. Impaired conversion of exogenous arachidonic and by platelets to thromboxane b2 and correction of that deficiency by interferon-alpha.  Prostaglandins. 1990;  40 351-360
• 30 Martyre M C. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.  Leuk Lymphoma. 1995;  20 39-44
• 31 Le Bousse-Kerdiles M C, Martyre M C. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.  Pathol Biol (Paris). 2001;  49 153-157
• 32 Martyre M C, Magdelenat H, Calvo F. Interferon gamma in vivo reverses the increased platelet levels of platelet-derived growth factors in transforming growth factor-13 in patients with myelofibrosis with myeloid metaplasia.  Br J Haematol. 1991;  77 431-435
• 33 Michiels J J, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia).  Int J Hematol. 2002;  76 133-145
• 34 Silver R T, Woolf S H, Hehlmann R et al.. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.  Blood. 1999;  94 1515-1516
• 35 Ellis J, Silver R T, Coleman M et al.. The bone marrow in polycythemia vera.  Semin Hematol. 1975;  12 433-444
• 36 Michiels J J, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia).  Int J Haemat. 2002;  76 133-145
• 37 Jones A, Silver R T, Waghorn K et al.. Minimal molecular response in polycythemia vera patents treated with imatinib or interferon alpha.  Blood. 2006;  107 3339-3341
• 38 Poncz M. BACH and the megakaryocyte symphony.  Blood. 2005;  105 3001-3002